Understanding the cancer stem cell von Bomken, S, Fišer, K, Heidenreich, O, Vormoor, J

Volltext

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitina... von Garrido Castro, P, van Roon, E H J, Pinhanços, S S, Trentin, L, Schneider, P, Kerstjens, M, te Kronnie, G, Heidenreich, O, Pieters, R, Stam, R W

Volltext

A robust post-insertion method for the preparation of targeted siRNA LNPs von Swart, L.E., Koekman, C.A., Seinen, C.W., Issa, H., Rasouli, M., Schiffelers, R.M., Heidenreich, O.

Volltext

Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia von Elder, A, Bomken, S, Wilson, I, Blair, H J, Cockell, S, Ponthan, F, Dormon, K, Pal, D, Heidenreich, O, Vormoor, J

Volltext

Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia von Pal, D, Blair, H J, Elder, A, Dormon, K, Rennie, K J, Coleman, D J L, Weiland, J, Rankin, K S, Filby, A, Heidenreich, O, Vormoor, J

Volltext

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO von Goyama, S, Schibler, J, Gasilina, A, Shrestha, M, Lin, S, Link, K A, Chen, J, Whitman, S P, Bloomfield, C D, Nicolet, D, Assi, S A, Ptasinska, A, Heidenreich, O, Bonifer, C, Kitamura, T, Nassar, N N, Mulloy, J C

Volltext

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding von Ptasinska, A, Assi, S A, Mannari, D, James, S R, Williamson, D, Dunne, J, Hoogenkamp, M, Wu, M, Care, M, McNeill, H, Cauchy, P, Cullen, M, Tooze, R M, Tenen, D G, Young, B D, Cockerill, P N, Westhead, D R, Heidenreich, O, Bonifer, C

Volltext

The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype von Forster, V J, Nahari, M H, Martinez-Soria, N, Bradburn, A K, Ptasinska, A, Assi, S A, Fordham, S E, McNeil, H, Bonifer, C, Heidenreich, O, Allan, J M

Volltext

New insights to the MLL recombinome of acute leukemias von Meyer, C, Kowarz, E, Hofmann, J, Renneville, A, Zuna, J, Trka, J, Ben Abdelali, R, Macintyre, E, De Braekeleer, E, De Braekeleer, M, Delabesse, E, de Oliveira, M P, Cavé, H, Clappier, E, van Dongen, J J M, Balgobind, B V, van den Heuvel-Eibrink, M M, Beverloo, H B, Panzer-Grümayer, R, Teigler-Schlegel, A, Harbott, J, Kjeldsen, E, Schnittger, S, Koehl, U, Gruhn, B, Heidenreich, O, Chan, L C, Yip, S F, Krzywinski, M, Eckert, C, Möricke, A, Schrappe, M, Alonso, C N, Schäfer, B W, Krauter, J, Lee, D A, zur Stadt, U, Te Kronnie, G, Sutton, R, Izraeli, S, Trakhtenbrot, L, Lo Nigro, L, Tsaur, G, Fechina, L, Szczepanski, T, Strehl, S, Ilencikova, D, Molkentin, M, Burmeister, T, Dingermann, T, Klingebiel, T, Marschalek, R

Volltext

P314: THERAPEUTICALLY TARGETING THE UNIQUE BARCODE OF MLL/AF4 von Cameron, R., Swart, L., Rasouli, M., Heidenreich, O.

Volltext

The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO von Duque-Afonso, J, Yalcin, A, Berg, T, Abdelkarim, M, Heidenreich, O, Lübbert, M

Volltext

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia von Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schröder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M

Volltext

The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia von Eswaran, J, Sinclair, P, Heidenreich, O, Irving, J, Russell, L J, Hall, A, Calado, D P, Harrison, C J, Vormoor, J

Volltext

Pontin is a critical regulator for AML1-ETO-induced leukemia von Breig, O, Bras, S, Martinez Soria, N, Osman, D, Heidenreich, O, Haenlin, M, Waltzer, L

Volltext

Differential expression of miR-17 similar to 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia von Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schroder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M

Volltext

P465: A LIPID NANOPARTICLE DELIVERY SYSTEM FOR TARGETING THE LEUKAEMIC FUSION GENE RUNX1/ETO BY SIRNA von Swart, L., Derevyanko, P., Oort, A., Ashtiani, M., Krippner‐Heidenreich, A., Koekman, A., Seinen, C., Issa, H., Blair, H., Schiffelers, R., Heidenreich, O.

Volltext

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance von Weiland, J, Pal, D, Case, M, Irving, J, Ponthan, F, Koschmieder, S, Heidenreich, O, von Stackelberg, A, Eckert, C, Vormoor, J, Elder, A

Volltext

Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression von Bomken, S, Buechler, L, Rehe, K, Ponthan, F, Elder, A, Blair, H, Bacon, C M, Vormoor, J, Heidenreich, O

Volltext

P309: IMAGE‐BASED HIGH‐CONTENT DRUG SENSITIVITY SCREENING IDENTIFIES CONVENTIONAL, EMERGING, AND POTENTIAL NOVEL THERAPEUTIC TARGETS IN HIGH‐RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA... von Bell, H., Singh, M., Blair, H., Poll, A., Law, E., Heidenreich, O., Delft, F., Moorman, A., Lunec, J., Irving, J.

Volltext

Bleeding Complications after Endovascular Therapy of Cerebral Arteriovenous Malformations von Heidenreich, J.O, Hartlieb, S, Stendel, R, Pietila, T.A, Schlattmann, P, Wolf, K.-J, Schilling, A.M

Volltext